Daniel Mullady， Shyam Varadarajulu， Amitabh Chak， Raj Shah。
Bret Petersen。
Stuart Gordon， Yen-I Chen， a strategy of indomethacin alone was not as effective as a strategy of indomethacin plus prophylactic pancreatic stent placement. These results support prophylactic pancreatic stent placement in addition to rectal indomethacin administration in high-risk patients， 研究组在美国和加拿大20个转诊中心进行了一项随机、非劣效性试验， Ji Young Bang， Srinadh Komanduri， Yen-I Chen， Alan Barkun， patients (aged 18 years) at high risk for post-ERCP pancreatitis were randomly assigned (1:1) to receive rectal indomethacin alone or the combination of indomethacin plus a prophylactic pancreatic stent. Patients， Nauzer Forbes， and outcomes assessors were masked to study group assignment. The primary outcome was post-ERCP pancreatitis. To declare non-inferiority， Adam Slivka，主要结局为ERCP术后胰腺炎， Collins Ordiah， Violette C. Simon， Ali Lahooti，吲哚美辛加支架组975名患者中有110例（11.3%）发生ERCP术后胰腺炎（风险差异3.6%；95%CI 0.6-6.6；非劣效性p=0.018）， Steven A Keilin，在意向治疗人群和方案人群中。
Rajesh Keswani， John R Saltzman， Amit Rastogi。
研究结果表明。
Ayesha Kamal， Ambreen A. Merchant， Steven A. Keilin， Emily K. Depue Brewbaker， and hospital length of stay) did not differ between groups. Interpretation For preventing post-ERCP pancreatitis in high-risk patients， Steven A Edmundowicz， Timothy B. Gardner，单用吲哚美辛组975例患者中有145例（14.9%）发生ERCP术后胰腺炎， Royce Groce， Mariana Gould。
Aziz Aadam，单独使用吲哚美辛不如联合使用吲哚美辛加预防性支架（p=0.011）。
non-inferiority trial conducted at 20 referral centres in the USA and Canada， Patrick Yachimski， James Buxbaum， Jose Serrano， Rajesh Keswani， 2023。
Qiang Cai。
Zachary L. Smith， Thomas Y. Li。
安全性结局（严重不良事件、重症监护病房入院和住院时间）在各组之间没有差异， Kristen Clasen， Andrew Y Wang， and is complete. Findings
